EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA

A K Kakkar iD, Marc P Bonaca, Robert P Giugliano, Karen Pieper, Dan Bloomfield, Bruce Hug, Janeen Salter, Debra Freedholm, Sanobar Parkar, Saverio Virdone, Herman Sandeep Prakasam iD, Meg Fluharty und 3 weitere

PLOS One · 28.07.2026 · 21 (7) · e0354382

DOI: 10.1371/journal.pone.0354382 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 28.07.2026. Verfasst von A K Kakkar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis Research Institute, London, United Kingdom. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Anticoagulants. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Thrombosis Research Institute (TRI), London, UK and Anthos Therapeutics - a Novartis Company (Boston, USA). TRI and Anthos Therapeutics were involved in st….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GARDENIA is a global, multicentre, prospective, non-interventional study in high-risk atrial fibrillation (AF) patients, who were untreated with anticoagulants.

Objectives

Provide contemporary evidence on reasons for non-treatment with an anticoagulant, and outcomes in high-risk AF patients.

Methods

GARDENIA enrolled 704 AF patients with a CHA 2 DS 2 -VA score ≥2 and an elevated risk of bleeding (older age (≥70 years), reduced renal function, concomitant antiplatelet or NSAID use, or other conditions associated with increased bleeding risk), and had not been recently treated with an oral anticoagulant (OAC). Patients were followed for at least 4 months. The two-year risks of mortality, stroke and major bleeding with or without direct OACs (DOACs) in these patients was estimated using the GARFIELD risk score.

Results

History of major bleeding (18.7%), physician-assessed high-risk of bleeding (17.1%), and patient refusal (17.6%) were the top reasons for not initiating OACs. The 100-person-year event rates (95% CI) for mortality, stroke/systemic embolism (SE)/transient ischemic attack (TIA), and ISTH major bleeding were 13.22 (10.33, 16.92), 2.12 (1.14, 3.94), and 2.21 (1.13, 3.91), respectively. GARFIELD risk analysis indicated a 31% and 40% increase in the risk of mortality and stroke, respectively, and a ~ 30% decrease in risk of major bleeding, compared to the estimated risk, had the patients been anticoagulated. The study was prematurely terminated due to low rate of patient accrual.

Conclusions

Perceived risk of bleeding was the leading cause for non-treatment with OACs in high-risk AF patients. Risk prediction modelling indicated that the benefits of anticoagulation in stroke and mortality reduction outweigh the risk of bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeAnticoagulantsHumansFemaleAgedMaleHemorrhageAged, 80 and overProspective StudiesRisk FactorsMiddle Aged

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Thrombosis Research Institute, London, United Kingdom.
  • CPC Clinical Research/CPC Community Health, Aurora, Colorado, United States of America.
  • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Anthos Therapeutics - A Novartis Company, Cambridge, Massachusetts, United States of America.

ORCID-Profile: A K Kakkar, Herman Sandeep Prakasam, Keith A A Fox

Förderung

  • The Thrombosis Research Institute (TRI), London, UK and Anthos Therapeutics - a Novartis Company (Boston, USA). TRI and Anthos Therapeutics were involved in st…

Zitieren

APA

Kakkar, A. K., Bonaca, M. P., Giugliano, R. P., Pieper, K., Bloomfield, D., Hug, B., Salter, J., Freedholm, D., Parkar, S., Virdone, S., Prakasam, H. S., Fluharty, M., Kayani, G., Fox, K. A. A., & GARDENIA investigators (2026). Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA. PLOS One, 21(7), e0354382. https://doi.org/10.1371/journal.pone.0354382

Vancouver

Kakkar AK, Bonaca MP, Giugliano RP, Pieper K, Bloomfield D, Hug B, et al. Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA. PLOS One. 2026;21(7):e0354382. doi:10.1371/journal.pone.0354382

BibTeX
@article{Kakkar2026,
  author = {Kakkar, A K and Bonaca, Marc P and Giugliano, Robert P and Pieper, Karen and Bloomfield, Dan and Hug, Bruce and Salter, Janeen and Freedholm, Debra and Parkar, Sanobar and Virdone, Saverio and Prakasam, Herman Sandeep and Fluharty, Meg and Kayani, Gloria and Fox, Keith A A and GARDENIA investigators, GARDENIA investigators},
  title = {Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0354382},
  doi = {10.1371/journal.pone.0354382}
}
Kostenlos starten →